Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Résumé
Background: Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date.Patients and methods: In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance (CrCl) was calculated before each cycle according to the Cockroft and Gault formula. Definition criteria for local control after neoadjuvant chemotherapy included pathological complete response (ypT0N0), pathological downstaging (
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
Accord Elsevier CCSD : Connectez-vous pour contacter le contributeur
https://hal.science/hal-03625944
Soumis le : lundi 8 janvier 2024-08:02:07
Dernière modification le : mardi 22 octobre 2024-12:18:03
Dates et versions
Licence
Identifiants
- HAL Id : hal-03625944 , version 1
- DOI : 10.1016/j.clgc.2021.08.005
- PII : S1558-7673(21)00162-2
- PUBMED : 34602349
- WOS : 000731363100020
Citer
Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
Collections
386
Consultations
53
Téléchargements